Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Baxter
Boehringer Ingelheim
McKinsey

Last Updated: May 28, 2022

Investigational Drug Information for AZD5363


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for AZD5363?

AZD5363 is an investigational drug.

There have been 30 clinical trials for AZD5363. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Cancer Research UK.

There are one hundred and thirty-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for AZD5363
TitleSponsorPhase
Capivasertib China PK StudyAstraZenecaPhase 1
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerDaiichi Sankyo Company, LimitedPhase 1
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerAstraZenecaPhase 1

See all AZD5363 clinical trials

Clinical Trial Summary for AZD5363

Top disease conditions for AZD5363
Top clinical trial sponsors for AZD5363

See all AZD5363 clinical trials

US Patents for AZD5363

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD5363 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
AZD5363 See Plans and Pricing Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) See Plans and Pricing
AZD5363 See Plans and Pricing Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) See Plans and Pricing
AZD5363 See Plans and Pricing Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide AstraZeneca AB (Sodertalje, SE) See Plans and Pricing
AZD5363 See Plans and Pricing 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD5363

Drugname Country Document Number Estimated Expiration Related US Patent
AZD5363 Australia AU2015244171 2034-04-11 See Plans and Pricing
AZD5363 Australia AU2015244179 2034-04-11 See Plans and Pricing
AZD5363 Canada CA2945128 2034-04-11 See Plans and Pricing
AZD5363 Canada CA2945129 2034-04-11 See Plans and Pricing
AZD5363 China CN106414451 2034-04-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.